8-K: Benitec Biopharma Flags Financial Statement Non-Reliance

Benitec Biopharma Inc. announced that its Audit Committee concluded that previously issued financial statements for Q2 and Q3 2025 should no longer be relied upon due to incorrect share-based compensation expense recording.

Summary

• Benitec Biopharma Inc. determined that it had not appropriately recorded certain non-cash share-based compensation expenses in prior periods.
• On September 10, 2025, the Audit Committee concluded that the unaudited consolidated financial statements for the three and nine months ended March 31, 2025, and the three and six months ended December 31, 2024, should no longer be relied upon.
• The errors resulted from an incorrectly configured new information recording system, implemented in November 2023, used to calculate share-based compensation expense.
• This led to understatements of share-based compensation expense, additional paid-in capital, accumulated deficit, net loss, and loss per share.
• The cumulative impact of these errors was material for the quarterly periods ended December 31, 2024, and March 31, 2025.
• The Company is preparing restatements of these financial statements to be included in the Annual Report on Form 10-K for the fiscal year ended June 30, 2025.
• The 2025 Form 10-K is expected to be filed on a timely basis, on or prior to its deadline.
• The Audit Committee and management have discussed these matters with Baker Tilly US, LLP, the Company's independent registered public accounting firm.

Sentiment

Score: 3

Explanation: The restatement of financial statements due to material errors, even if non-cash, is a significant negative event that can erode investor confidence and suggests internal control weaknesses. The timely filing of the 10-K with restatements is a minor positive, but the core issue is negative.

Positives

• The Company is actively addressing the issue by preparing restatements.
• The 2025 Form 10-K is expected to be filed on a timely basis, indicating no delay in the annual report itself.
• The identified errors are non-cash in nature.

Negatives

• Previously issued unaudited consolidated financial statements for Q2 and Q3 2025 cannot be relied upon.
• Share-based compensation expense was understated, leading to understatements of additional paid-in capital, accumulated deficit, net loss, and loss per share.
• The cumulative impact of the errors was material for the affected quarterly periods.
• The need for restatement indicates a weakness in internal controls or accounting processes related to the new information system.

Risks

• Reliance on previously issued financial statements for Q2 and Q3 2025 is no longer appropriate.
• Potential for investor uncertainty or loss of confidence due to financial restatements.
• Risks detailed under the caption "Risk Factors" in the Company's most recently filed Annual Report on Form 10-K and in other reports filed with the SEC.

Future Outlook

The Company expects to file its Annual Report on Form 10-K for the fiscal year ended June 30, 2025, which will include the restated financial statements, on a timely basis, on or prior to the deadline.

Management Comments

• We expect to file the 2025 Form 10-K with the SEC on a timely basis, on or prior to the deadline for the 2025 Form 10-K.

Industry Context

This announcement is specific to Benitec Biopharma's internal accounting processes and does not reflect broader industry trends. However, financial restatements can impact investor confidence, a common concern across all industries.

Comparison to Industry Standards

• NA. This filing addresses an internal accounting error rather than operational or financial performance that can be directly compared to industry benchmarks or specific competitor results.

Corporate Governance

Stakeholder Impact

• Shareholders: May experience decreased confidence due to unreliable past financial reporting and potential negative impact on share price.
• Investors: Will need to re-evaluate the company's financial health based on restated figures.
• Management: Faces increased scrutiny regarding internal controls and financial reporting accuracy.
• Auditors: Independent registered public accountants (Baker Tilly US, LLP) are involved in the discussion and will be reviewing the restated financials.

Next Steps

• Preparation of restatements of the Prior Financial Statements.
• Inclusion of restated financial statements in the 2025 Form 10-K.
• Filing of the 2025 Form 10-K with the SEC on a timely basis.

Key Dates

Recommendation

While the restatement of financial statements due to material errors is a significant negative, the errors are non-cash and the company is taking immediate steps to correct them and file the annual report on time. This indicates a commitment to transparency and remediation. Investors should hold to observe the impact of the restated financials and any subsequent actions taken to strengthen internal controls, rather than selling immediately based on an accounting correction.

Keywords

Benitec Biopharma, BNTC, SEC filing, 8-K, financial restatement, share-based compensation, accounting error, non-reliance, financial statements, audit committee, Nasdaq